CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
14 hedge funds and large institutions have $2.15M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
74% less capital invested
Capital invested by funds: $8.44M → $2.15M (-$6.29M)
Holders
14
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$319K | |
| 2 | +$245K | |
| 3 | +$173K | |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$118K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$16.6K |
Top Sellers
| 1 | -$6.92M | |
| 2 | -$312K | |
| 3 | -$20.9K | |
| 4 |
Morgan Stanley
New York
|
-$6.78K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.88K |